Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392869 | 0.97 | SMN1; SMN2 (0.48) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL395074 | 0.96 | SMN1; SMN2 (0.53) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL392861 | 0.94 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL3939630 | 0.93 | SMN1; SMN2 (0.51) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL394999 | 0.92 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL3943100 | 0.90 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL3939100 | 0.90 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL394043 | 0.90 | SMN1; SMN2 (0.58) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL395078 | 0.89 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2NPSR1HTT | |
| SCHEMBL3939564 | 0.88 | HTT (0.48) | MEN1KMT2ASMN1; SMN2NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009023411-A1 | COMPOSITIONS AND METHODS FOR TREATING OR CONTROLLING ANTERIOR- AND POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2009-02-19 | — | — | WO | claimed |
| US-20070021418-A1 | Method of inhibiting production of osteopontin | KOWA CO., LTD. (JP) | 2007-01-25 | — | — | US | claimed |
| EP-1650195-A1 | METHOD OF INHIBITING PRODUCTION OF OSTEOPONTIN | Kowa Co., Ltd. (JP) | 2006-04-26 | — | — | EP | claimed |
| US-8101207-B2 | Composition containing medicine extremely slightly soluble in water and method for preparation thereof | KOWA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070021418-A1 | Method of inhibiting production of osteopontin | KOWA CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1650195-A1 | METHOD OF INHIBITING PRODUCTION OF OSTEOPONTIN | Kowa Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MEN1 4721/4885KMT2A 3295/4885SMN1; SMN2 1505/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | MEN1 4680/4885KMT2A 3727/4885SMN1; SMN2 906/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MEN1 4730/4885KMT2A 3265/4885SMN1; SMN2 1584/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MEN1 4779/4885KMT2A 3177/4885SMN1; SMN2 1410/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | MEN1 4798/4885KMT2A 3861/4885SMN1; SMN2 1744/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MEN1 4779/4885KMT2A 3177/4885SMN1; SMN2 1410/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MEN1 4779/4885KMT2A 3177/4885SMN1; SMN2 1410/4885 |
| US-20070021418-A1 | Method of inhibiting production of osteopontin | HDGF, PGF, FGF23 | MEN1 884/4885KMT2A 4691/4885SMN1; SMN2 3853/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MEN1 4730/4885KMT2A 3265/4885SMN1; SMN2 1584/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | MEN1 4798/4885KMT2A 3861/4885SMN1; SMN2 1744/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MEN1 4721/4885KMT2A 3295/4885SMN1; SMN2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.